Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Recent Insights into Mucinous Ovarian Carcinoma.

Ricci F, Affatato R, Carrassa L, Damia G.

Int J Mol Sci. 2018 May 24;19(6). pii: E1569. doi: 10.3390/ijms19061569. Review.

2.

Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines.

Restelli V, Lupi M, Vagni M, Chilà R, Bertoni F, Damia G, Carrassa L.

Target Oncol. 2018 Apr;13(2):235-245. doi: 10.1007/s11523-018-0553-6.

PMID:
29441438
3.

A High-throughput Screening of a Chemical Compound Library in Ovarian Cancer Stem Cells.

Ricci F, Carrassa L, Christodoulou MS, Passarella D, Michel B, Benhida R, Martinet N, Hunyadi A, Ioannou E, Roussis V, Musso L, Dallavalle S, Silvestri R, Westwood N, Mori M, Ingallina C, Botta B, Kavetsou E, Detsi A, Majer Z, Hudecz F, Bosze S, Kaminska B, Hansen TV, Bertrand P, Athanassopoulos CM, Damia G.

Comb Chem High Throughput Screen. 2018;21(1):50-56. doi: 10.2174/1386207321666180124093406.

PMID:
29366408
4.

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.

Tarantelli C, Gaudio E, Arribas AJ, Kwee I, Hillmann P, Rinaldi A, Cascione L, Spriano F, Bernasconi E, Guidetti F, Carrassa L, Pittau RB, Beaufils F, Ritschard R, Rageot D, Sele A, Dossena B, Rossi FM, Zucchetto A, Taborelli M, Gattei V, Rossi D, Stathis A, Stussi G, Broggini M, Wymann MP, Wicki A, Zucca E, Cmiljanovic V, Fabbro D, Bertoni F.

Clin Cancer Res. 2018 Jan 1;24(1):120-129. doi: 10.1158/1078-0432.CCR-17-1041. Epub 2017 Oct 24.

PMID:
29066507
5.

DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy.

Carrassa L, Damia G.

Cancer Treat Rev. 2017 Nov;60:139-151. doi: 10.1016/j.ctrv.2017.08.013. Epub 2017 Sep 19. Review.

PMID:
28961555
6.

Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation.

Restelli V, Vagni M, Arribas AJ, Bertoni F, Damia G, Carrassa L.

Br J Haematol. 2018 Apr;181(1):129-133. doi: 10.1111/bjh.14506. Epub 2016 Dec 26. No abstract available.

PMID:
28025833
7.

Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer.

Ubezio P, Falcetta F, Carrassa L, Lupi M.

Oncotarget. 2016 Mar 29;7(13):15492-506. doi: 10.18632/oncotarget.7491.

8.

Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.

Restelli V, Chilà R, Lupi M, Rinaldi A, Kwee I, Bertoni F, Damia G, Carrassa L.

Oncotarget. 2015 Nov 10;6(35):37229-40. doi: 10.18632/oncotarget.5954.

9.

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.

Chilà R, Basana A, Lupi M, Guffanti F, Gaudio E, Rinaldi A, Cascione L, Restelli V, Tarantelli C, Bertoni F, Damia G, Carrassa L.

Oncotarget. 2015 Feb 20;6(5):3394-408.

10.

Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.

Rastelli G, Anighoro A, Chripkova M, Carrassa L, Broggini M.

Cell Cycle. 2014;13(14):2296-305. doi: 10.4161/cc.29295. Epub 2014 Jun 9.

11.

Chk1-Mad2 interaction: a crosslink between the DNA damage checkpoint and the mitotic spindle checkpoint.

Chilà R, Celenza C, Lupi M, Damia G, Carrassa L.

Cell Cycle. 2013 Apr 1;12(7):1083-90. doi: 10.4161/cc.24090. Epub 2013 Mar 1.

12.

Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.

Carrassa L, Chilà R, Lupi M, Ricci F, Celenza C, Mazzoletti M, Broggini M, Damia G.

Cell Cycle. 2012 Jul 1;11(13):2507-17. doi: 10.4161/cc.20899. Epub 2012 Jul 1.

PMID:
22713237
13.

Unleashing Chk1 in cancer therapy.

Carrassa L, Damia G.

Cell Cycle. 2011 Jul 1;10(13):2121-8. Epub 2011 Jul 1. Review.

PMID:
21610326
14.

p38alpha as an inducer of aneuploidy in p53-/- tetraploid cells.

Carrassa L.

Cell Cycle. 2010 Aug 1;9(15):2928. doi: 10.4161/cc.9.15.12629. Epub 2010 Aug 1. No abstract available.

PMID:
20703078
15.

Role of Chk1 in the differentiation program of hematopoietic stem cells.

Carrassa L, Montelatici E, Lazzari L, Zangrossi S, Simone M, Broggini M, Damia G.

Cell Mol Life Sci. 2010 May;67(10):1713-22. doi: 10.1007/s00018-010-0274-1. Epub 2010 Feb 10.

PMID:
20146081
16.

U2OS cells lacking Chk1 undergo aberrant mitosis and fail to activate the spindle checkpoint.

Carrassa L, Sanchez Y, Erba E, Damia G.

J Cell Mol Med. 2009 Aug;13(8A):1565-76. doi: 10.1111/j.1582-4934.2009.00362.x.

17.

The cytotoxic effect of unconjugated bilirubin in human neuroblastoma SH-SY5Y cells is modulated by the expression level of MRP1 but not MDR1.

Corich L, Aranda A, Carrassa L, Bellarosa C, Ostrow JD, Tiribelli C.

Biochem J. 2009 Jan 1;417(1):305-12. doi: 10.1042/BJ20080918.

PMID:
18713069
18.

Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil.

Ganzinelli M, Carrassa L, Crippa F, Tavecchio M, Broggini M, Damia G.

Clin Cancer Res. 2008 Aug 15;14(16):5131-41. doi: 10.1158/1078-0432.CCR-08-0304.

19.

Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53.

Carrassa L, Broggini M, Erba E, Damia G.

Cell Cycle. 2004 Sep;3(9):1177-81. Epub 2004 Sep 13.

PMID:
15326376
20.

Characterization of the 5'flanking region of the human Chk1 gene: identification of E2F1 functional sites.

Carrassa L, Broggini M, Vikhanskaya F, Damia G.

Cell Cycle. 2003 Nov-Dec;2(6):604-9.

PMID:
14504477
21.

Unique features of the mode of action of ET-743.

D'Incalci M, Erba E, Damia G, Galliera E, Carrassa L, Marchini S, Mantovani R, Tognon G, Fruscio R, Jimeno J, Faircloth GT.

Oncologist. 2002;7(3):210-6. Review.

22.

Cisplatinum and taxol induce different patterns of p53 phosphorylation.

Damia G, Filiberti L, Vikhanskaya F, Carrassa L, Taya Y, D'incalci M, Broggini M.

Neoplasia. 2001 Jan-Feb;3(1):10-6.

23.

Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways.

Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth GT, Liberi G, Foiani M, D'Incalci M.

Int J Cancer. 2001 May 15;92(4):583-8.

Supplemental Content

Loading ...
Support Center